Carbamazepine in the treatment of neuroleptic malignant syndrome

被引:13
作者
Thomas, P [1 ]
Maron, M [1 ]
Rascle, C [1 ]
Cottencin, O [1 ]
Vaiva, G [1 ]
Goudemand, M [1 ]
机构
[1] Univ Lille 2, Ctr Hosp Reg & Univ Lille, Dept Psychiat, Sch Med, F-59037 Lille, France
关键词
carbamazepine; neuroleptic malignant syndrome; neuroleptic; adverse event; treatment; affective disorder;
D O I
10.1016/S0006-3223(97)00450-2
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Background: Neuroleptic malignant syndrome (NMS) is a potentially lethal adverse effect to neuroleptic drugs. Methods: We report on 2 cases where NMS dramatically improved with carbamazepine, incidental removal and reapplication of carbamazepine attests to its effectiveness for this condition. Results: A 34-year-old woman treated for a major depressive disorder experienced NMS with a phenothiazine, Her condition dramatically improved in 8 hours after she was administered carbamazepine. Since carbamazepine was discontinued, NMS recurred in 10 hours and remitted anew within less than 24 hours after reintroduction. A 31-year-old woman experiencing a schizoaffective disorder displayed NMS with aphenothiazine and a butyrophenone. none. NMS completely resolved within 8 hours after she was administered carbamazepine. NMS recurred within 12 hours after carbamazepine discontinuation. Conclusions: These data thus account for a cause-effect relationship between carbamazepine administration and NMS relief and argue against the neuroleptic withdrawal to be responsible by itself for NMS relief. (C) 1998 Society of Biological Psychiatry.
引用
收藏
页码:303 / 305
页数:3
相关论文
共 15 条
[1]   NEUROLEPTIC MALIGNANT SYNDROME - REVIEW AND ANALYSIS OF 115 CASES [J].
ADDONIZIO, G ;
SUSMAN, VL ;
ROTH, SD .
BIOLOGICAL PSYCHIATRY, 1987, 22 (08) :1004-1020
[2]   NEUROLEPTIC MALIGNANT SYNDROME [J].
BUCKLEY, PF ;
HUTCHINSON, M .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1995, 58 (03) :271-273
[3]  
CLARK M, 1995, BRAIN RES MOL BRAIN, V26, P309
[4]   CARBAMAZEPINE AND NMS [J].
COULTER, F ;
CORRIGAN, FM .
BRITISH JOURNAL OF PSYCHIATRY, 1991, 158 :434-435
[5]   CARBAMAZEPINE AND FORME-FRUSTE NEUROLEPTIC MALIGNANT SYNDROME [J].
DALKIN, T ;
LEE, AS .
BRITISH JOURNAL OF PSYCHIATRY, 1990, 157 :437-438
[6]   Neuroleptic malignant syndrome and catatonia: One entity or two? [J].
Fink, M .
BIOLOGICAL PSYCHIATRY, 1996, 39 (01) :1-4
[7]   CONCOMITANT TREATMENT OF NEUROLEPTIC MALIGNANT SYNDROME AND PSYCHOSIS [J].
GOLDWASSER, HD ;
HOOPER, JF ;
SPEARS, NM .
BRITISH JOURNAL OF PSYCHIATRY, 1989, 154 :102-104
[8]   ENZYME ELEVATIONS IN THE NEUROLEPTIC MALIGNANT SYNDROME [J].
GURRERA, RJ ;
ROMERO, JA .
BIOLOGICAL PSYCHIATRY, 1993, 34 (09) :634-640
[9]  
KEEPERS GA, 1990, AM J PSYCHIAT, V147, P1687
[10]   Diagnostic and Statistical Manual of Mental Disorders [J].
Mittal, Vijay A. ;
Walker, Elaine F. .
PSYCHIATRY RESEARCH, 2011, 189 (01) :158-159